Your browser doesn't support javascript.
loading
Reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) by SARS-CoV-2 in non-hospitalised HIV-infected patients.
Lambarey, Humaira; Blumenthal, Melissa J; Chetram, Abeen; Joyimbana, Wendy; Jennings, Lauren; Orrell, Catherine; Schäfer, Georgia.
Afiliação
  • Lambarey H; International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, South Africa; Division of Medical Biochemistry, Department of Integrative Biomedical Sci
  • Blumenthal MJ; International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, South Africa; Division of Medical Biochemistry, Department of Integrative Biomedical Sci
  • Chetram A; International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa.
  • Joyimbana W; Desmond Tutu Health Foundation, Cape Town, South Africa.
  • Jennings L; Desmond Tutu Health Foundation, Cape Town, South Africa.
  • Orrell C; Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, South Africa; Desmond Tutu Health Foundation, Cape Town, South Africa.
  • Schäfer G; International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, South Africa; Division of Medical Biochemistry, Department of Integrative Biomedical Sci
EBioMedicine ; 100: 104986, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38306893
ABSTRACT

BACKGROUND:

While acute SARS-CoV-2 infection and associated inflammation resulted in substantial morbidity and mortality during the COVID-19 pandemic, particularly in unvaccinated patients, long-term effects of SARS-CoV-2 exposure for reactivation of latent oncogenic herpesviruses, such as KSHV, is unknown.

METHODS:

We performed a longitudinal observational cross-sectional study on 407 non-hospitalised adult HIV-infected (CD4 count <350 cells/µL) patients attending antiretroviral therapy services in Gugulethu, South Africa, from October 2020 to April 2023.

FINDINGS:

KSHV seroprevalence was 53.5%; the quarterly SARS-CoV-2 seroprevalence increased from 76.2% (before roll-out of COVID-19 vaccinations) to 94.9%, with 32.2% being self-reportedly vaccinated against COVID-19. Over the course of recruitment, the quarterly percentage of patients with detectable KSHV viral load (VL) in the peripheral blood increased from 3.3% to 69.2%. The presence of KSHV VL was significantly associated with SARS-CoV-2 RBD antibody titers in unvaccinated (median RBD IgG OD 1.24 [IQR 0.82-2.42] in non-reactivated versus 2.83 [IQR 1.08-4.72] in reactivated patients, p = 0.0030) but not in vaccinated patients (median RBD IgG OD 5.13 [IQR 4.11-6.36] in non-reactivated versus 4.53 [IQR 2.90-5.92] in reactivated patients, p = 0.086). Further logistic regression revealed significantly higher odds of KSHV reactivation in unvaccinated, previously SARS-CoV-2 exposed patients (p = 0.015, adjusted OR 1.28 [95% CI 1.05-1.55]), but not vaccinated patients (p = 0.080, adjusted OR 0.83 [95% CI 0.67-1.02]). Interestingly, detectable KSHV VL was not associated with increased inflammatory markers such as C-reactive protein and interleukin-6.

INTERPRETATION:

High, and most likely repeated, exposure to SARS-CoV-2 in unvaccinated individuals may have long-term consequences for reactivation of KSHV infection as shown here in the context of HIV-infected patients with impaired immune functions. Post-pandemic prevention and/or monitoring strategies of potential KSHV-associated pathologies in high-risk patients with immunodeficiencies are therefore highly recommended.

FUNDING:

This research was funded by the EDCTP2 programme (Training and Mobility Action TMA2018SF-2446).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Kaposi / Infecções por HIV / Herpesvirus Humano 8 / COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: EBioMedicine Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma de Kaposi / Infecções por HIV / Herpesvirus Humano 8 / COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Revista: EBioMedicine Ano de publicação: 2024 Tipo de documento: Article